332 related articles for article (PubMed ID: 30483476)
1. Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.
Chin C; Lunking ES; de la Fuente M; Ayad NG
Front Oncol; 2018; 8():521. PubMed ID: 30483476
[TBL] [Abstract][Full Text] [Related]
2. Advances in immunotherapy for glioblastoma multiforme.
Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
Front Immunol; 2022; 13():944452. PubMed ID: 36311781
[TBL] [Abstract][Full Text] [Related]
3. A narrative review of research progress on drug therapies for glioblastoma multiforme.
Zheng X; Tang Q; Ren L; Liu J; Li W; Fu W; Wang J; Du G
Ann Transl Med; 2021 Jun; 9(11):943. PubMed ID: 34350258
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications.
Das S; Dash BS; Premji TP; Chen JP
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445721
[TBL] [Abstract][Full Text] [Related]
5. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.
Jackson C; Ruzevick J; Phallen J; Belcaid Z; Lim M
Clin Dev Immunol; 2011; 2011():732413. PubMed ID: 22190972
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM).
Yalamarty SSK; Filipczak N; Li X; Subhan MA; Parveen F; Ataide JA; Rajmalani BA; Torchilin VP
Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046777
[TBL] [Abstract][Full Text] [Related]
7. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
8. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
9. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.
Yeo AT; Charest A
J Cell Biochem; 2017 Sep; 118(9):2516-2527. PubMed ID: 28230277
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy and Response Assessment in Malignant Glioma: Neuro-oncology Perspective.
Bagley SJ; Desai AS; Nasrallah MP; O'Rourke DM
Top Magn Reson Imaging; 2020 Apr; 29(2):95-102. PubMed ID: 32271286
[TBL] [Abstract][Full Text] [Related]
12. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives.
Sener U; Ruff MW; Campian JL
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806051
[TBL] [Abstract][Full Text] [Related]
14. Barriers to overcoming immunotherapy resistance in glioblastoma.
Gillette JS; Wang EJ; Dowd RS; Toms SA
Front Med (Lausanne); 2023; 10():1175507. PubMed ID: 37275361
[TBL] [Abstract][Full Text] [Related]
15. Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers.
Lechpammer M; Rao R; Shah S; Mirheydari M; Bhattacharya D; Koehler A; Toukam DK; Haworth KJ; Pomeranz Krummel D; Sengupta S
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406398
[TBL] [Abstract][Full Text] [Related]
16. Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors.
Nicholas S; Mathios D; Ruzevick J; Jackson C; Yang I; Lim M
Brain Tumor Res Treat; 2013 Apr; 1(1):2-8. PubMed ID: 24904882
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
18. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
[TBL] [Abstract][Full Text] [Related]
19. A review of glioblastoma immunotherapy.
Medikonda R; Dunn G; Rahman M; Fecci P; Lim M
J Neurooncol; 2021 Jan; 151(1):41-53. PubMed ID: 32253714
[TBL] [Abstract][Full Text] [Related]
20. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
Majd N; de Groot J
Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
[No Abstract] [Full Text] [Related]
[Next] [New Search]
